Patents by Inventor Alphonse J. Langlois

Alphonse J. Langlois has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
    Publication number: 20100291680
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: June 2, 2010
    Publication date: November 18, 2010
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, JR., Alphonse J. Langlois
  • Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7122190
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 17, 2006
    Assignee: Duke University
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
    Publication number: 20040052820
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Application
    Filed: October 8, 2002
    Publication date: March 18, 2004
    Applicants: Duke University, Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O?apos;Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
    Patent number: 6479055
    Abstract: The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus (“RSV”) transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1LAI transmembrane protein (TM) gp41.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 12, 2002
    Assignee: Trimeris, Inc.
    Inventors: Dani Paul Bolognesi, Thomas James Matthews, Carl T. Wild, Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois
  • Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
    Patent number: 6017536
    Abstract: The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107.times.178.times.4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: January 25, 2000
    Assignee: Trimeris, Inc.
    Inventors: Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway, Alphonse J. Langlois